文拉法辛联合盐酸哌甲酯对发作性睡病的初步疗效观察

Clinical effect of venlafaxine combined with methylphenidate hydrochloride on narcolepsy

探讨文拉法辛缓释胶囊联合盐酸哌甲酯片对发作性睡病的临床疗效。38例发作性睡病患者随机分为文拉法辛缓释胶囊联合盐酸哌甲酯片治疗组(观察组)和盐酸哌甲酯联合氯米帕明(氯丙米嗪)治疗组(对照组),每组19例,连续治疗12周,观察两组患者临床疗效及药物不良反应。结果显示,观察组患者白天过度嗜睡(15/19对8/19,P=0.044)和猝倒(13/19对6/19,P=0.048)治疗有效率高于对照组,药物不良反应发生率低于对照组(χ2=8.889,P=0.003)。提示文拉法辛联合盐酸哌甲酯治疗发作性睡病患者的白天过度嗜睡和猝倒症状有较好疗效。

This study aims to explore the clinical effect of venlafaxine sustained release capsules combined with methylphenidate hydrochloride tablets on narcolepsy. Thirty eight cases of narcoleptic patients were randomly divided into venlafaxine combined with methylphenidate hydrochloride treatment group(observation group, N = 19) and methylphenidate hydrochloride and clomipramine treatment group(control group, N = 19). After a total of 12 week treatment, clinical curative effect and adverse drug reactions were observed in 2 groups of patients. The results showed that effective rate of the treatment for excessive daytime sleepiness(EDS) in observation group was higher than that of the control group(15/19 vs 8/19, P = 0.044), and effective rate of the treatment for cataplexy in observation group was higher than that of the control group(13/19 vs 6/19, P=0.048). The rate of adverse drug reactions in observation group was lower than that in the control group(χ2=8.889, P=0.003). It was indicated that venlafaxine combined with methylphenidate had good curative effect on narcolepsy with EDS and cataplexy symptoms.